505 related articles for article (PubMed ID: 30347660)
1. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
2. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
3. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
4. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
7. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
8. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
Janaka SK; Lucas TM; Johnson MC
J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
[TBL] [Abstract][Full Text] [Related]
9. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
Blanchet FP; Mitchell JP; Piguet V
Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
[TBL] [Abstract][Full Text] [Related]
10. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
Lucas TM; Lyddon TD; Cannon PM; Johnson MC
J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
[TBL] [Abstract][Full Text] [Related]
11. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
12. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.
Tokarev AA; Munguia J; Guatelli JC
J Virol; 2011 Jan; 85(1):51-63. PubMed ID: 20980512
[TBL] [Abstract][Full Text] [Related]
13. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
14. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
15. BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
Richard J; Prévost J; von Bredow B; Ding S; Brassard N; Medjahed H; Coutu M; Melillo B; Bibollet-Ruche F; Hahn BH; Kaufmann DE; Smith AB; Sodroski J; Sauter D; Kirchhoff F; Gee K; Neil SJ; Evans DT; Finzi A
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331088
[TBL] [Abstract][Full Text] [Related]
16. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
18. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
[TBL] [Abstract][Full Text] [Related]
20. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
Dubé M; Bego MG; Paquay C; Cohen ÉA
Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]